Enhanced Th1 responses in tumor-specific CD4+ and CD8+ T cells and natural killer cells in mice were superior after treatment with SFV-IL-18 and recombinant IL-12 than with IL-12 alone. The gene discussed is CD8A; the disease is neoplasm.